IP Library › Granted Patent US 12,447,149
Granted Patent B2
US 12,447,149 · App. 19/079,070 · Granted Oct 21, 2025

Formulations of vimseltinib

Inventor: Ehab Hamed (Waltham, MA)
Assignee: Deciphera Pharmaceuticals, LLC
A61K31/513A61K9/4825A61K9/485A61K9/4858A61K9/4866C07D401/14A61K9/0053
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,447,149
App. No.
19/079,070
Granted
Oct 21, 2025
Kind
B2
Abstract

Described herein, in part, are pharmaceutically acceptable formulations comprising a compound represented by Formula (I) and methods of preparing and using the formulations:

Claims (36)

1. A pharmaceutically acceptable uniform oral dosage form comprising:

a crystalline dihydrate form of a compound of Formula (I):

wherein the crystalline dihydrate form is present in the oral dosage form in an amount selected from the group consisting of about 15.2 mg, about 21.7 mg, and about 32.5 mg;

about 70% by weight to about 90% by weight lactose monohydrate based on the total weight of the oral dosage form;

about 1% by weight to about 10% by weight cross-linked polyvinylpyrrolidone based on the total weight of the uniform oral dosage form; and

about 0.1% by weight to about 3% by weight of one or more lubricants based on the total weight of the oral dosage form;

wherein the uniform oral dosage form has an acceptance value of less than about 15 as determined by United States Pharmacopeia (USP) Uniformity of Dosage Unit <905>, wherein the crystalline dihydrate form of the compound of Formula (I) has an X-ray powder diffraction (XRPD) pattern comprising peaks, in terms of 2-theta, at about 10.9°, 16.8°, and 27.1° as measured by CuKa radiation.

2. The pharmaceutically acceptable uniform oral dosage form of claim 1 , where in wherein the uniform oral dosage form has not more than about 10 mol % of a crystalline form of the compound of Formula (I) not having a diffraction pattern comprising peaks in terms of 2-theta, at about 10.9°, 16.8°, and 27.1° as measured by CuKa radiation.

3. The pharmaceutically acceptable uniform oral dosage form of claim 1 , where in wherein the uniform oral dosage form has not more than about 5 mol % of a crystalline form of the compound of Formula (I) not having a diffraction pattern comprising peaks in terms of 2-theta, at about 10.9°, 16.8°, and 27.1° as measured by CuKa radiation.

4. The pharmaceutically acceptable uniform oral dosage form of claim 1 , where in wherein the uniform oral dosage form has not more than about 3 mol % of a crystalline form of the compound of Formula (I) not having a diffraction pattern comprising peaks in terms of 2-theta, at about 10.9°, 16.8°, and 27.1° as measured by CuKa radiation.

5. The pharmaceutically acceptable uniform oral dosage form of claim 1 , where in wherein the uniform oral dosage form has not more than about 1 mol % of a crystalline form of the compound of Formula (I) not having a diffraction pattern comprising peaks in terms of 2-theta, at about 10.9°, 16.8°, and 27.1° as measured by CuKa radiation.

6. The pharmaceutically acceptable uniform oral dosage form of claim 1 , wherein the crystalline dihydrate form of the compound of Formula (I) has having an XRPD pattern substantially as shown in FIG. 1 .

7. The pharmaceutically acceptable uniform oral dosage form of claim 1 , wherein the crystalline dihydrate form of the compound of Formula (I) has having a differential scanning calorimetry (DSC) thermogram comprising an endothermic event with onset between about 75° C. to about 95° C., an exothermic event with onset between about 123° C. to about 150° C., and an endothermic peak at about 215° C.

8. The pharmaceutically acceptable uniform oral dosage form of claim 1 , wherein the crystalline dihydrate form of the compound of Formula (I) has having a differential scanning calorimetry (DSC) thermogram substantially as shown in FIG. 2 .

9. The pharmaceutically acceptable uniform oral dosage form of claim 1 , wherein the crystalline dihydrate form of the compound of Formula (I) has having a thermogravimetric analysis (TGA) thermogram substantially as shown in FIG.

10. The pharmaceutically acceptable uniform oral dosage form of claim 1 , wherein the crystalline dihydrate form of the compound of Formula (I) has an X-ray powder diffraction XRPD pattern comprising peaks, in terms of 2-theta, at about 5.9°, 10.9°, 11.9°, 13.7°, 16.8°, and 27.1° as measured by CuKa radiation.

11. A pharmaceutically acceptable capsule encapsulating a uniform pharmaceutical composition comprising:

a solid-state dihydrate form of a compound represented by Formula (I):

wherein the solid-state dihydrate form of the compound of Formula (I) is present in the capsule in an amount to provide about 2 mg, about 10 mg, about 14 mg, about 20 mg or about 30 mg of the free base of the compound;

a means for making the composition uniform with an acceptance value of less than 15 according to USP <905>; and

one or more pharmaceutically acceptable excipients, wherein the solid-state dihydrate form of the compound represented by Formula (I) has an X-ray powder diffraction (XRPD) pattern comprising peaks, in terms of 2-theta, at about 10.9°, 16.8°, and 27.1° as measured by CuKa radiation.

12. The pharmaceutically acceptable capsule of claim 11 , wherein the one or more pharmaceutically acceptable excipients comprises: about 1% by weight to about 20% by weight of one or more disintegrants based on the weight of the uniform pharmaceutical composition; and about 0.1% by weight to about 10% by weight of one or more lubricants based on the weight of the pharmaceutically acceptable unit formulation uniform pharmaceutical composition.

13. The pharmaceutically acceptable capsule of claim 11 , wherein the one or more pharmaceutically acceptable excipients comprises: about 1% by weight to about 10% by weight of one or more disintegrants based on the weight of the uniform pharmaceutical composition; and about 0.1% by weight to about 3% by weight of one or more lubricants based on the weight of the pharmaceutically acceptable unit formulation uniform pharmaceutical composition.

14. The pharmaceutically acceptable capsule of claim 11 , where in the one or more pharmaceutically acceptable excipients includes about 1% by weight to about 10% by weight cross-linked polyvinylpyrrolidone based on the weight of the uniform pharmaceutical composition.

15. The pharmaceutically acceptable capsule of claim 11 , wherein the solid-state dihydrate form of the compound of Formula (I) has an X-ray powder diffraction XRPD pattern comprising peaks, in terms of 2-theta, at about 5.9°, 10.9°, 11.9°, 13.7°, 16.8°, and 27.1° as measured by CuKa radiation.

16. The pharmaceutically acceptable capsule of claim 11 , wherein the solid-state dihydrate form of the compound of Formula (I) has having an XRPD pattern substantially as shown in FIG. 1 .

17. An oral dosage form comprising a compound of Formula (I):

wherein the compound is present in the oral dosage form as a free base, or a pharmaceutically acceptable salt of the compound and wherein the free base or pharmaceutically acceptable salt is in a crystalline dihydrate hydrate form; wherein the compound crystalline dihydrate form is present in the oral dosage form in an amount to provide about 2 mg, about 10 mg, about 14 mg, about 20 mg or about 30 mg of the free base of the compound;

about 80% by weight to about 90% by weight of a filler based on the total weight of the oral dosage form, wherein the filler is selected from the group consisting of anhydrous lactose, lactose monohydrate, and lactose dihydrate;

about 1% by weight to about 10% by weight cross-linked polyvinylpyrrolidone based on the total weight of the uniform oral dosage form; and

about 0.1% by weight to about 3% by weight by weight of one or more lubricants based on the total weight of the oral dosage form, wherein the one or more lubricants are selected from the group consisting of sodium lauryl sulfate, magnesium stearate, aluminum stearate, calcium stearate, sodium stearyl fumarate, stearic acid and magnesium lauryl stearate, wherein the crystalline dihydrate form of the compound of Formula (I) has an X-ray powder diffraction pattern (XRPD) pattern comprising peaks, in terms of 2-theta, at about 10.9°, 16.8°, and 27.1° as measured by CuKa radiation.

18. The oral dosage form of claim 17 , wherein greater than 90% of the compound of Formula (I) is released in 30 minutes, as determined by USP <711>, Apparatus 2 (paddles).

19. The oral dosage form of claim 17 , wherein the one or more lubricants is magnesium stearate.

20. The oral dosage form of claim 17 , wherein the filler is lactose monohydrate.

21. The oral dosage form of claim 17 , wherein the crystalline dihydrate form of the compound of Formula (I) has an XRPD pattern comprising peaks, in terms of 2-theta, at about 5.9°, 10.9°, 11.9°, 13.7°, 16.8°, and 27.1° as measured by CuKa radiation.

22. The oral dosage form of claim 17 , wherein the crystalline dihydrate form of the compound of Formula (I) has an XRPD pattern substantially as shown in FIG. 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2025
From: HAMED, EHAB AHMED MAMDOUH
To: DECIPHERA PHARMACEUTICALS, LLC
Reel/Frame 071800/0676 →
Continuity (3)
Continuation 18971846 · Dec 6, 2024
Provisional Application 63607697 · Dec 8, 2023
Related Publication 20250205236A1 · Jun 26, 2025
References Cited (215)
US 7144911B2 · Flynn et al. · 2006 [cited by applicant]
US 7202257B2 · Flynn et al. · 2007 [cited by applicant]
US 7279576B2 · Flynn et al. · 2007 [cited by applicant]
US 7342037B2 · Flynn et al. · 2008 [cited by applicant]
US 7531566B2 · Flynn et al. · 2009 [cited by applicant]
US 7666895B2 · Flynn et al. · 2010 [cited by applicant]
US 7737283B2 · Flynn et al. · 2010 [cited by applicant]
US 7790756B2 · Flynn et al. · 2010 [cited by applicant]
US 7897762B2 · Flynn et al. · 2011 [cited by applicant]
US 8143293B2 · Flynn et al. · 2012 [cited by applicant]
US 8163756B2 · Flynn et al. · 2012 [cited by applicant]
US 8188113B2 · Flynn et al. · 2012 [cited by applicant]
US 8278331B2 · Flynn et al. · 2012 [cited by applicant]
US 8461179B1 · Flynn et al. · 2013 [cited by applicant]
US 8486951B2 · Flynn et al. · 2013 [cited by applicant]
US 8569319B2 · Flynn et al. · 2013 [cited by applicant]
US 8586565B2 · Flynn et al. · 2013 [cited by applicant]
US 8637672B2 · Flynn et al. · 2014 [cited by applicant]
US 8741911B2 · Allgeier et al. · 2014 [cited by applicant]
US 8921565B2 · Flynn et al. · 2014 [cited by applicant]
US 8940756B2 · Flynn et al. · 2015 [cited by applicant]
US 9012635B2 · Flynn et al. · 2015 [cited by applicant]
US 9133183B2 · Flynn et al. · 2015 [cited by applicant]
US 9181223B2 · Kaufman et al. · 2015 [cited by applicant]
US 9187474B2 · Flynn et al. · 2015 [cited by applicant]
US 9193719B2 · Flynn et al. · 2015 [cited by applicant]
US 9309224B2 · Flynn et al. · 2016 [cited by applicant]
US 9334267B2 · Flynn et al. · 2016 [cited by applicant]
US 9382228B2 · Flynn et al. · 2016 [cited by applicant]
US 9387202B2 · Flynn et al. · 2016 [cited by applicant]
US 9457019B2 · Flynn et al. · 2016 [cited by applicant]
US 11103507B2 · Flynn et al. · 2021 [cited by applicant]
US 11679110B2 · Flynn et al. · 2023 [cited by applicant]
US 20080214544A1 · Bellon et al. · 2008 [cited by applicant]
US 20080255155A1 · Raeppel et al. · 2008 [cited by applicant]
US 20100120806A1 · Flynn et al. · 2010 [cited by applicant]
US 20100166699A1 · Thompson et al. · 2010 [cited by applicant]
US 20110053906A1 · Huck et al. · 2011 [cited by applicant]
US 20140145025A1 · Fang et al. · 2014 [cited by applicant]
US 20150073129A1 · Herting et al. · 2015 [cited by applicant]
US 20190091217A1 · Flynn et al. · 2019 [cited by applicant]
US 20200129489A1 · Flynn et al. · 2020 [cited by applicant]
US 20200352920A1 · Flynn et al. · 2020 [cited by applicant]
US 20200354346A1 · Flynn et al. · 2020 [cited by applicant]
US 20200354352A1 · Flynn et al. · 2020 [cited by applicant]
US 20210015801A1 · Flynn et al. · 2021 [cited by applicant]
US 20230414614A1 · Flynn et al. · 2023 [cited by applicant]
CN 105120864A · 2015 [cited by applicant]
CN 105473617A · 2016 [cited by applicant]
CN 113880812A · 2022 [cited by applicant]
CN 116283919A · 2023 [cited by applicant]
EP 3632907A1 · 2020 [cited by applicant]
EP 3682881A1 · 2020 [cited by applicant]
JP 6364472B2 · 2018 [cited by applicant]
RU 2330024C2 · 2008 [cited by applicant]
WO WO2003000660A1 · 2003 [cited by applicant]
WO WO2008079291A2 · 2008 [cited by applicant]
WO WO2010051373A1 · 2010 [cited by applicant]
WO 2014145015A2 · 2014 [cited by applicant]
WO 2014145028A2 · 2014 [cited by applicant]
WO WO2014145025A2 · 2014 [cited by applicant]
WO WO2020139828A1 · 2020 [cited by applicant]
WO WO2022247786A1 · 2022 [cited by applicant]
Cao et al. (CN 116283919A) abstract Jun. 23, 2023 (Year: 2023). [cited by examiner]
Caira M. R. et al. “Crystalline Polymorphism of Organic Compounds”, Design of Organic Solids. Topics in Current Chemistry, vol. 198, p. 163-208 (1998). [cited by applicant]
Fang Z. et al. Conformational restriction: an effective tactic in ‘follow-on’-based drug discovery, Fugure Med Chem. 2014, 6(8): 885-901. [cited by applicant]
Kumari A. et al. 3D-QSAR analysis of anilinoquinoline inhibitors of colony stimulating factor-1 kinase(cFMS): implementation of field-based molecular alignment, Med Chem Res 22, 5167-5183 (2013). [cited by applicant]
PCT/US2019/068311 International Search Report and Written Opinion mailed Jul. 2, 2020. [cited by applicant]
PCT/US2024/058988 International Search Report and Written Opinion dated Mar. 24, 2025. [cited by applicant]
Silverman R.B. et al. Lead Discovery, The Organic Chemistry of Drug Design and Drug Action, 3rd Ed, Chapter 2, pp. 19-122, Elsevier (2014). [cited by applicant]
“Deciphera Pharmaceuticals Announces Positive, Preliminary, Top-Line Clinical Data for the Ongoing Phase 1 Clincial Study with DCC-3014 and an Update on Future Development Plans,” 2019, 1-3. [cited by applicant]
“History of Changes for Study: NCT03069469 Study of DCC-3014 in Patients with Advanced Malignancies,” ClinicalTrials.gov Archive, 2018, 1-5. [cited by applicant]
Al-Muhsen et al., “The Expression of Stem Cell Factor and c-Kit Receptor in Human Asthmatic Airways,” Clinical and Experimental Allergy, 2004, 34: 911-917. [cited by applicant]
Attoub et al., “The C-Kit Tyrosine Kinase Inhibitor STI571 for Colorectal Cancer Therapy,” Cancer Research, 2002, 62: 4879-4883. [cited by applicant]
Blay, JY et al., “P63: Patient-Reported Outcomes Following Treatment with Vimseltinib for Tenosynovial Giant Cell Tumour in a Phase 2 Expansion Study”, Value in Health, Elsevier, Amsterdam, NL, vol. 25, No. 12 (Dec. 1, … [cited by applicant]
Boisson et al., “c-Kit and c-kit mutations in mastocytosis and other hematological diseases,” Journal of Leukocyte Biology, 2000, 67(2):135-148. [cited by applicant]
Brinkmann et al., “Fingolimod (FTY720): Discovery and Development of an Oral Drug to Treat Multiple Sclerosis,” Nature Reviews | Drug Discovery, 2010, 9: 883-897. [cited by applicant]
Brunton et al., “Chemotherapy of Neoplastic Diseases,” in, Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 2008, 11th ed.: 853-908. [cited by applicant]
Burns et al., “C-FMS Inhibitors: A Patent Review,” Expert Opinion on Therapeutic Patents, 2011, 147-165. [cited by applicant]
Caldwell, T. M. et al., “Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT),” Biorg. Med. Che… [cited by applicant]
Carvajal et al., “KIT as a Therapeutic Target in Metastatic Melanoma,” Journal of the American Medical Association, 2011, 305(22): 2327-2334. [cited by applicant]
Dewar et al., “Inhibition of c-fms by Imatinib: expanding the spectrum of treatment,” Cell Cycle, 2005, 4(7):851-853. [cited by applicant]
Dewar et al., “Macrophage Colony-Stimulating Factor Receptor C-Fms is a Novel Target of Imatinib,” Blood, 2005, 105(8): 3127-3132. [cited by applicant]
Di Lorenzo et al., “Expression of Proto-Oncogene C-Kit in High Risk Prostate Cancer,” European Journal of Surgical Oncology, 2004, 30: 987-992. [cited by applicant]
Dorwald, “Side Reactions in Organic Synthesis,” Wiley: VCH Weinhem Preface, 2005, 1-15 & 8: 279-308. [cited by applicant]
El Agamy et al., “Targeting c-Kit in the Therapy of Mast Cell Disorders: Current Update,” European Journal of Pharmacology, 2012, 690: 1-3. [cited by applicant]
Fine et al., “Neoplasms of the Central Nervous System,” Cancer Principles & Practice of Oncology, 2005, 1834-1887. [cited by applicant]
Fogarty et al., “Development of Protein Kinase Activators: AMPK as a Target in Metabolic Disorders and Cancer,” Biochimica et Biophysica Acta, 2010, 1804: 581-591. [cited by applicant]
Gelderblom, H. et al., “475P: Safety and Efficacy of Vimseltinib in Tenosynovial Giant Cell Tumour (TGCT)): Long-term Phase I Update”, Annals of Oncology, vol. 33, (Sep. 1, 2022), p. S757, XP093241096. [cited by applicant]
Gelderblom, H. et al., “Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial”, The Lancet, vol. 403, No. 10445, (Jun. 3, 2024… [cited by applicant]
Girouard et al., “Neurovascular Coupling in the Normal Brain and in Hypertension, Stroke, and Alzheimer Disease,” J. Appl Physiol., 2006, 100: 328-335. [cited by applicant]
Gupta et al., “IL-3 Inhibits Human Osteoclastogenesis and Bone Resorption through Downregulation of c-Fms and Diverts the Cells to Dendritic Cell Lineage,” The Journal of Immunology, 2010, 2261-2272. [cited by applicant]
Heinrich et al., “Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor,” Blood, 2000, 96(3):925-932. [cited by applicant]
Henriksen et al., “Assessment of Osteoclast Number and Function: Application in the Development of New and Improved Treatment Modalities for Bone Diseases,” Osteoporosis International, 2006, 18: 681-685. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2014/029661 mailed Jun. 11, 2014. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2014/029664 mailed Jun. 11, 2014. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2019/068311 mailed Feb. 7, 2020. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2024/053261 mailed Feb. 6, 2025. [cited by applicant]
Judge et al., “Potassium Channel Blockers in Multiple Sclerosis: Neuronal Kv Channels and Effects of Symptomatic Treatment,” Pharmacology & Therapeutics, 2006, 224-259. [cited by applicant]
Kung et al., “Structure Activity Relationships of Quinoline-Containing c-Met Inhibitors,” European Journal of Medicinal Chemistry 43, 2008, 1321-1329. [cited by applicant]
Kuster et al., “Kinase Inhibitors Methods and Protocols,” Methods in Molecular Biology, 2012, 1-46. [cited by applicant]
Lewitt, “Levodopa for the Treatment of Parkinson's Disease,” New England Journal of Medicine, 2008, 359: 2468-2476. [cited by applicant]
Luo et al., “Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction,” Cell, 2009, 36: 823-837. [cited by applicant]
Minkin, “Bone Acid Phosphatase: Tartrate-Resistant Acid Phosphatase as a Marker of Osteoclast Function,” Calcified Tissue International, 1982, 34: 285-290. [cited by applicant]
Mitchell et al., “Amyotrophic Lateral Sclerosis,” The Lancet, 2007, 369: 2031-2041. [cited by applicant]
National Cancer Institute (http://www.cancer.gov) 2014. [cited by applicant]
O'Brien et al., “Vascular Cognitive Impairment,” The Lancet Neurology, 2003, 2: 89-98. [cited by applicant]
Ohno et al., “A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model,” Mol Cancer Ther., 2006, 5(11):2634-2643. [cited by applicant]
Pyonteck et al., “CSF-1R inhibition alters macrophage polarization and blocks glioma progression,” Nature Medicine, 2013, 19(10):1264-1274. [cited by applicant]
Reber et al., “Stem Cell Factor and its Receptor c-Kit as Targets for Inflammatory Diseases,” European Journal of Pharmacology, 2006, 533: 327-340. [cited by applicant]
Roberts et al., “Antiangiogenic and Antitumor Activity of a Selective PDGFR Tyrosine Kinase Inhibitor, CP-673, 451,” Cancer Research, 2005, 957-966. [cited by applicant]
Rubin et al., “KIT activation is a ubiquitous feature of gastrointestinal stromal tumors,” Cancer Research, 2001, 61(22):8118-8121. [cited by applicant]
Shah et al., “Current Approaches in the Treatment of Alzheimer's Disease,” Biomedicine & Pharmacotherapy, 2008, 62: 199-207. [cited by applicant]
Smith, B. D. et al., “Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages”, Molecular Cancer Therapeutics, vol. 20, No. 11, (Aug. 25, 2021), pp. 2098-2109, XP09… [cited by applicant]
Tap et al., “Pexidartinib Versus Placebo for Advanced Tenosynovial Giant Cell Tumour (ENLIVEN): a Randomised Phase 3 Trial,” Lancet, 2019, 394: 478-487. [cited by applicant]
Tap et al., “Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor,” New England Journal of Medicine, 2015, 373(5):428-437. [cited by applicant]
Tap, W. D. et al., “Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial”, Journal of Clinical Oncology, vol. 42, No. 16_su… [cited by applicant]
Tap, W. D. et al., “MOTION: A randomized, phase 3, placebo-controlled, double-blind study of vimseltinib (DCC-3014) for the treatment of tenosynovial giant cell tumour”, Journal of Clinical Oncology, vol. 40, No. 16_sup… [cited by applicant]
Wen et al., “Osteosarcoma Cell-Intrinsic Colony Stimulating Factor-1 Receptor Functions to Promote Tumor Cell Metastasis Through JAG1 Signaling,” American Journal of Cancer Research, 2017, 7(4): 801-815. [cited by applicant]
Yasuda et al., “The Stem Cell Factor/C-Kit Receptor Pathway Enhance Proliferation and Invasion of Pancreatic Cancer Cells,” Molecular Cancer, 2006, 5(46): 1-10. [cited by applicant]
U.S. Appl. No. 11/963,740, filed Dec. 21, 2007, Patented, U.S. Pat. No. 8,163,756. [cited by applicant]
U.S. Appl. No. 11/870,388, filed Oct. 10, 2007, Patented, U.S. Pat. No. 7,790,756. [cited by applicant]
U.S. Appl. No. 12/829,561, filed Jul. 2, 2010, Patented, U.S. Pat. No. 8,586,565. [cited by applicant]
U.S. Appl. No. 11/854,354, filed Sep. 12, 2007, Patented, U.S. Pat. No. 8,188,113. [cited by applicant]
U.S. Appl. No. 10/746,460, filed Dec. 24, 2003, Patented, U.S. Pat. No. 7,144,911. [cited by applicant]
U.S. Appl. No. 10/886,329, filed Jul. 6, 2004, Patented, U.S. Pat. No. 7,202,257. [cited by applicant]
U.S. Appl. No. 11/450,840, filed Jun. 9, 2006, Patented, U.S. Pat. No. 7,342,037. [cited by applicant]
U.S. Appl. No. 11/336,708, filed Jan. 20, 2006, Patented, U.S. Pat. No. 7,531,566. [cited by applicant]
U.S. Appl. No. 11/450,850, filed Jun. 9, 2006, Patented, U.S. Pat. No. 7,666,895. [cited by applicant]
U.S. Appl. No. 10/746,607, filed Dec. 24, 2003, Patented, U.S. Pat. No. 7,279,576. [cited by applicant]
U.S. Appl. No. 11/854,293, filed Sep. 12, 2007, Patented, U.S. Pat. No. 7,897,762. [cited by applicant]
U.S. Appl. No. 12/105,408, filed Apr. 18, 2008, Patented, U.S. Pat. No. 8,143,293. [cited by applicant]
U.S. Appl. No. 13/590,955, filed Aug. 21, 2012, Patented, U.S. Pat. No. 8,486,951. [cited by applicant]
U.S. Appl. No. 11/450,849, filed Jun. 9, 2006, Patented, U.S. Pat. No. 7,737,283. [cited by applicant]
U.S. Appl. No. 13/785,575, filed Mar. 5, 2013, Patented, U.S. Pat. No. 8,741,911. [cited by applicant]
U.S. Appl. No. 12/608,578, filed Oct. 29, 2009, Patented, U.S. Pat. No. 8,278,331. [cited by applicant]
U.S. Appl. No. 13/098,247, filed Apr. 29, 2011, Patented, U.S. Pat. No. 8,569,319. [cited by applicant]
U.S. Appl. No. 13/559,170, filed Jul. 26, 2012, Patented, U.S. Pat. No. 8,637,672. [cited by applicant]
U.S. Appl. No. 14/214,134, filed Mar. 14, 2014, Patented, U.S. Pat. No. 9,133,183. [cited by applicant]
U.S. Appl. No. 14/383,803, filed Mar. 5, 2013, Patented, U.S. Pat. No. 9,187,474. [cited by applicant]
U.S. Appl. No. 13/491,394, filed Jun. 7, 2012, Patented, U.S. Pat. No. 8,461,179. [cited by applicant]
U.S. Appl. No. 13/801,753, filed Mar. 13, 2013, Patented, U.S. Pat. No. 8,940,756. [cited by applicant]
U.S. Appl. No. 16/387,315, filed Apr. 17, 2019, Pending. [cited by applicant]
U.S. Appl. No. 14/214,127, filed Mar. 14, 2014, Patented, U.S. Pat. No. 9,012,635. [cited by applicant]
U.S. Appl. No. 13/683,277, filed Nov. 21, 2012, Patented, U.S. Pat. No. 8,921,565. [cited by applicant]
U.S. Appl. No. 14/549,125, filed Nov. 20, 2014, Patented, U.S. Pat. No. 9,387,202. [cited by applicant]
U.S. Appl. No. 14/214,160, filed Mar. 14, 2014, Patented, U.S. Pat. No. 9,193,719. [cited by applicant]
U.S. Appl. No. 14/214,171, filed Mar. 14, 2014, Patented, U.S. Pat. No. 9,181,223. [cited by applicant]
U.S. Appl. No. 14/214,185, filed Mar. 14, 2014, Patented, U.S. Pat. No. 9,382,228. [cited by applicant]
U.S. Appl. No. 14/214,179, filed Mar. 14, 2014, Patented, U.S. Pat. No. 9,309,224. [cited by applicant]
U.S. Appl. No. 14/383,799, filed Mar. 5, 2013, Patented, U.S. Pat. No. 9,334,267. [cited by applicant]
U.S. Appl. No. 14/535,900, filed Nov. 7, 2014, Patented, U.S. Pat. No. 9,457,019. [cited by applicant]
U.S. Appl. No. 16/943,821, filed Jul. 30, 2020, Pending, US 2021-0145805 A1. [cited by applicant]
U.S. Appl. No. 16/943,871, filed Jul. 30, 2020, Pending, US 2020-0352920 A1. [cited by applicant]
U.S. Appl. No. 16/725,282, filed Dec. 23, 2019, Patented, U.S. Pat. No. 11,103,507. [cited by applicant]
U.S. Appl. No. 16/870,384, filed May 8, 2020, Patented, U.S. Pat. No. 11,530,206. [cited by applicant]
U.S. Appl. No. 16/870,418, filed May 8, 2020, Patented, U.S. Pat. No. 11,518,758. [cited by applicant]
U.S. Appl. No. 16/902,989, filed Jun. 16, 2020, Patented, U.S. Pat. No. 11,590,134. [cited by applicant]
U.S. Appl. No. 16/991,644, filed Aug. 12, 2020, Pending, US 2022-0047573 A1. [cited by applicant]
U.S. Appl. No. 17/028,640, filed Sep. 22, 2020, Pending, U.S. Pat. No. 10,966,966. [cited by applicant]
U.S. Appl. No. 17/180,234, filed Feb. 19, 2021, Patented, U.S. Pat. No. 11,585,535. [cited by applicant]
U.S. Appl. No. 17/180,241, filed Feb. 19, 2021, Patented, U.S. Pat. No. 11,395,818. [cited by applicant]
U.S. Appl. No. 17/504,133, filed Oct. 18, 2021, Patented, U.S. Pat. No. 11,576,103. [cited by applicant]
U.S. Appl. No. 18/314,348, filed May 9, 2023, Patented, U.S. Pat. No. 11,801,237. [cited by applicant]
U.S. Appl. No. 17/358,137, filed Jun. 25, 2021, Patented, U.S. Pat. No. 11,679,110. [cited by applicant]
U.S. Appl. No. 17/583,977, filed Jan. 25, 2022, Patented, U.S. Pat. No. 11,436,390. [cited by applicant]
U.S. Appl. No. 17/583,985, filed Jan. 22, 2022, Patented, U.S. Pat. No. 11,344,536. [cited by applicant]
U.S. Appl. No. 17/727,307, filed Apr. 22, 2022, Patented, U.S. Pat. No. 11,534,432. [cited by applicant]
U.S. Appl. No. 17/735,820, filed May 3, 2022, Patented, U.S. Pat. No. 11,612,591. [cited by applicant]
U.S. Appl. No. 18/148,766, filed Dec. 30, 2022, Patented, U.S. Pat. No. 11,896,585. [cited by applicant]
U.S. Appl. No. 17/845,275, filed Jun. 21, 2022, Pending, US 2022-0370423 A1. [cited by applicant]
U.S. Appl. No. 17/845,278, filed Jun. 21, 2022, Pending, US 2022-0370424 A1. [cited by applicant]
U.S. Appl. No. 17/180,218, filed Feb. 19, 2021, Patented, U.S. Pat. No. 11,266,635. [cited by applicant]
U.S. Appl. No. 17/583,977, filed Jan. 25, 2022, Patented, U.S. Pat. No. 11,426,390. [cited by applicant]
U.S. Appl. No. 17/869,108, filed Jul. 20, 2022, Patented, U.S. Pat. No. 11,969,414. [cited by applicant]
U.S. Appl. No. 17/583,985, filed Jan. 25, 2022, Patented, U.S. Pat. No. 11,344,546. [cited by applicant]
U.S. Appl. No. 17/735,678, filed May 3, 2022, Patented, U.S. Pat. No. 11,529,336. [cited by applicant]
U.S. Appl. No. 17/735,682, filed May 3, 2022, Patented, U.S. Pat. No. 11,576,904. [cited by applicant]
U.S. Appl. No. 17/938,353, filed Oct. 6, 2022, Patented, U.S. Pat. No. 11,779,572. [cited by applicant]
U.S. Appl. No. 17/735,862, filed May 3, 2022, Patented, U.S. Pat. No. 11,433,056. [cited by applicant]
U.S. Appl. No. 18/091,743, filed Dec. 30, 2022, Patented, U.S. Pat. No. 11,813,251. [cited by applicant]
U.S. Appl. No. 18/140,942, filed Apr. 28, 2023, Pending, US 2023-0414614 A1. [cited by applicant]
U.S. Appl. No. 17/833,272, filed Jun. 6, 2022, Patented, U.S. Pat. No. 12,071,032. [cited by applicant]
U.S. Appl. No. 17/832,224, filed Jun. 3, 2022, Pending, US 2023-0047915 A1. [cited by applicant]
U.S. Appl. No. 18/078,269, filed Dec. 9, 2022, Pending, US 2023-0357179 A1. [cited by applicant]
U.S. Appl. No. 18/078,271, filed Dec. 9, 2022, Pending, US 2023-0257352 A1. [cited by applicant]
U.S. Appl. No. 18/073,721, filed Dec. 9, 2022, Pending, US 2024-0116877 A1. [cited by applicant]
U.S. Appl. No. 18/152,993, filed Jan. 11, 2023, Pending, US 2023-0338376 A1. [cited by applicant]
U.S. Appl. No. 18/464,519, filed Sep. 11, 2023, Pending, US 2024-0261270 A1. [cited by applicant]
U.S. Appl. No. 18/463,498, filed Sep. 8, 2023, Pending, US 2024-0197696 A1. [cited by applicant]
U.S. Appl. No. 18/490,188, filed Oct. 19, 2023, Patented, U.S. Pat. No. 11,911,370. [cited by applicant]
U.S. Appl. No. 18/490,197, filed Oct. 19, 2023, Patented, U.S. Pat. No. 11,918,564. [cited by applicant]
U.S. Appl. No. 18/512,447, filed Nov. 17, 2023, Pending. [cited by applicant]
U.S. Appl. No. 18/518,100, filed Nov. 22, 2023, Patented, U.S. Pat. No. 11,969,415. [cited by applicant]
U.S. Appl. No. 18/518,110, filed Nov. 22, 2023, Patented, U.S. Pat. No. 12,023,328. [cited by applicant]
U.S. Appl. No. 18/750,014, filed Jun. 21, 2024, Pending, US 2024-0342144 A1. [cited by applicant]
U.S. Appl. No. 18/758,007, filed Jun. 28, 2024, Pending, US 2024-0350466 A1. [cited by applicant]
U.S. Appl. No. 18/795,683, filed Aug. 6, 2024, Pending, U.S. Pat. No. 12,213,967. [cited by applicant]
U.S. Appl. No. 18/795,711, filed Aug. 6, 2024, Pending, U.S. Pat. No. 12,226,406. [cited by applicant]
U.S. Appl. No. 18/795,731, filed Aug. 6, 2024, Pending, U.S. Pat. No. 12,213,968. [cited by applicant]
U.S. Appl. No. 18/815,054, filed Aug. 26, 2024, Pending. [cited by applicant]
U.S. Appl. No. 18/985,885, filed Dec. 18, 2024, Pending. [cited by applicant]
U.S. Appl. No. 18/980,378, filed Dec. 13, 2024, Pending. [cited by applicant]
U.S. Appl. No. 18/971,800, filed Dec. 6, 2024, Pending. [cited by applicant]
U.S. Appl. No. 18/971,846, filed Dec. 6, 2024, Pending. [cited by applicant]
U.S. Appl. No. 18/980,426, filed Dec. 13, 2024, Pending. [cited by applicant]
U.S. Appl. No. 19/001,282, filed Dec. 9, 2024, Pending. [cited by applicant]
U.S. Appl. No. 19/079,010, filed Mar. 13, 2025, Pending. [cited by applicant]
U.S. Appl. No. 19/079,727, filed Mar. 14, 2025, Pending. [cited by applicant]
U.S. Appl. No. 19/079,965, filed Mar. 14, 2025, Pending. [cited by applicant]
U.S. Appl. No. 19/085,149, filed Mar. 20, 2025, Pending. [cited by applicant]
PCT/US2024/060067 International Search Report and Written Opinion mailed Apr. 10, 2025, 48 pages. [cited by applicant]
Khadka, P. et al., Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability, Asian Journal of Pharmaceutical Sciences, 9(6): 304-316 (2014). [cited by applicant]
PCT/US2024/058998 International Search Report and Written Opinion mailed Jun. 2, 2025, 11 pages. [cited by applicant]
PCT/US2025/027042 International Search Report and Written Opinion mailed Jul. 23, 2025, 12 pages. [cited by applicant]
Cited By (4)
US 12,616,683 US 12,617,775 US 12,643,883 US 12,708,617